Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market
Listing to fund the clinical development of sevuparin for sepsis/septic shock No pharmaceutical products are currently available that are specifically meant to treat patients with sepsis/septic shock STOCKHOLM, SWEDEN – 15 March 2021: Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, announces that it has appointed Sedermera Fondkommission as financial adviser to support its planned listing on Nasdaq First North Growth Market. The engagement of Sedermera Fondkommission follows the appointment of Claes Lindblad at Modus